FindMyRecallSubscribe
Class I: serious health riskTerminated

Mylan Pharmaceuticals Insulin Glargine Recall

Insulin Glargine (Insulin glargine-yfgn) Injection, 100 units/mL (U-100), 3 mL prefille…

Mylan Pharmaceuticals Inc · Morgantown, WV

Risk level
Class I
Reported by FDA
Aug 3, 2022
Recall ID
D-1292-2022
Check your lot numberHow we source this data

Summary

Mylan Pharmaceuticals recalled Insulin Glargine starting Jul 5, 2022. The FDA classified it as Class I (serious health risk) and published enforcement report D-1292-2022 on Aug 3, 2022. Reason: Labeling: Missing label: Label missing from some prefilled pens. Status: Terminated.

Why it was recalled

Labeling: Missing label: Label missing from some prefilled pens.

Product description

Insulin Glargine (Insulin glargine-yfgn) Injection, 100 units/mL (U-100), 3 mL prefilled pens (NDC 49502-394-71), packaged in cartons of 5 prefilled pens (NDC 49502-394-75), Rx only, Manufactured by: Mylan Pharmaceuticals Inc., Morgantown, WV 15317, Manufactured for: Mylan Specialty L.P., Morgantown, WV

Lot numbers, UPCs & expiration codes

Lot #: BF21002895, Exp. Date Aug 2023

Where it was sold

Product was distributed nationwide within the United States

What to do if you have this product

  • Compare the lot number and expiration date on your package with the codes above.
  • Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
  • If you have symptoms you think are related, contact your doctor. In an emergency call 911.
  • Report side effects to FDA MedWatch at 1-800-FDA-1088.

Recall details

Recall number
D-1292-2022
Classification
Class I
Status
Terminated
Recall initiated
Jul 5, 2022
FDA report date
Aug 3, 2022
Quantity
253,200 pens (50,650/5 per packs)
Recall type
Voluntary: Firm initiated
Recalling firm
Mylan Pharmaceuticals Inc

Original FDA data

Every field from FDA enforcement report D-1292-2022, exactly as published.

Show all FDA fields
City
Morgantown
State
WV
Status
Terminated
Country
United States
Event ID
90545
Address
5005 Greenbag Rd
Code information
Lot #: BF21002895, Exp. Date Aug 2023
Postal code
26501-7124
Report date
Aug 3, 2022
Product type
Drugs
Recall number
D-1292-2022
Classification
Class I
Recalling firm
Mylan Pharmaceuticals Inc
Product quantity
253,200 pens (50,650/5 per packs)
Termination date
Feb 26, 2024
Reason for recall
Labeling: Missing label: Label missing from some prefilled pens.
Voluntary / mandated
Voluntary: Firm initiated
Product description
Insulin Glargine (Insulin glargine-yfgn) Injection, 100 units/mL (U-100), 3 mL prefilled pens (NDC 49502-394-71), packaged in cartons of 5 prefilled pens (NDC 49502-394-75), Rx only, Manufactured by: Mylan Pharmaceuticals Inc., Morgantown, WV 15317, Manufactured for: Mylan Specialty L.P., Morgantown, WV
Distribution pattern
Product was distributed nationwide within the United States
Recall initiation date
Jul 5, 2022
Initial firm notification
Press Release
Center classification date
Jul 26, 2022

How we source this data

Source: U.S. Food and Drug Administration enforcement report D-1292-2022, published Aug 3, 2022. View the source record (openFDA) · FDA enforcement reports

Last checked against FDA data: . Content last changed: .

FindMyRecall is an independent service and is not affiliated with or endorsed by the FDA. This page simplifies the official record; the FDA or manufacturer notice is authoritative, so follow its instructions. Medication information here is not individualized medical advice.

How we source and update recall data · Report incorrect information

Other recent drug recalls